W. Daniel Hillis is a Founding Partner of Applied Invention, LLC., a research and development company creating a range of new products and services in software, hardware, and biotechnology. He is Professor of Research Medicine in the Keck School of Medicine at USC and is the Widney Professor of Engineering and Medicine at USC. Previously, Hillis was VP, R&D at Walt Disney Imagineering. Hillis was co-founder of Thinking Machines Corp., a leading innovator in massive parallel supercomputers and RAID disk arrays. In addition to conceiving and designing the company’s major products, he worked closely with customers in applying parallel computers to a wide range of problems in biology, physics, finance and engineering.
David Agus is one of the world’s leading cancer doctors and pioneering biomedical researchers. Over the past twenty years, he has received acclaim for his innovations in medicine and contributions to new technologies, which continue to change the perception of health and empower people around the world to maintain healthy lives. Dr. Agus is professor of medicine and engineering at the University of Southern California, where he leads USC’s Westside Cancer Center and Center for Applied Molecular Medicine. He serves as a CBS News contributor. An international leader in new technologies and approaches for personalized healthcare, he cofounded two revolutionary companies: Navigenics and Applied Proteomics with Danny Hillis. Dr. Agus’ first book, The End of Illness, was published in 2012 and is a New York Times #1 and international best seller, and subject of a PBS special. His new book, New York Times best selling A Short Guide to a Long Life, was published January 2014.
Dr. Blair has been a Partner of Domain since its founding in 1985. Present board memberships include Applied Proteomics, Astute Medical, aTyr Pharma, Cadence Pharmaceuticals, Clovis Oncology, CoDa Therapeutics, IntegenX, Meritage Pharma, NeuroPace, and Zogenix. Dr. Blair has over 40 years experience with venture and emerging growth companies. In the course of his experience, he has been involved in the creation and successful development at the Board level of over 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Dura Pharmaceuticals, GeneOhm Sciences, Molecular Dynamics, NuVasive, Pharmion and Volcano. A former managing director of Rothschild Inc., Dr. Blair was directly involved at a senior level with Rothschild/New Court venture capital activities from 1978 to 1985. From 1969 to 1978, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies. From 1961 to 1969, Dr. Blair was an engineering manager with RCA Corporation, during which time he received a David Sarnoff Fellowship. Dr. Blair currently serves on the Board of Directors of the Prostate Cancer Foundation, and he is on the Advisory Boards of the Department of Molecular Biology at Princeton University, the USC Stevens Institute for Innovation, and the Caltech Division of Chemistry and Chemical Engineering, and the Caltech Innovation Initiative.
Daniel Abrutyn is the President of Applied Minds, LLC, a research and development company that invents, designs and prototypes high technology products and systems. Applied Minds works on a diverse set of projects including biotechnology, database software, enterprise software, robotics, visualization systems and conceptual design. It also partners with leading corporations and the US Government by providing them with technology solutions for their most compelling opportunities or challenging problems. Since joining Applied Minds, Dan has led the formation of six new companies including Metaweb Technologies, Inc. (acquired by Google, Inc.).
Previously, Dan was the Operating Partner at BV Capital, an internet, media and communications focused venture capital fund, the CFO/COO of allbusiness.com, a small business portal, and the President of 1stUp.com, an internet service provider owned by CMGi, Inc. Dan began his career as an investment banker at Lazard Frères & Co. where he specialized in corporate finance and mergers and acquisitions. He currently serves on the board of directors of Applied Proteomics, Inc., PeoplePoint Systems, Inc. and TouchTable, Inc.
He is a graduate of the University of Pennsylvania.
Erik Holmlin has two decades of experience in the life science and health care industries. His expertise spans technology development and commercialization, global marketing, commercial operations, venture financing, mergers & acquisitions and intellectual property. Recently, he served as president and CEO of GenVault Corporation, a life science company bringing innovative solutions to biosample management. He merged GenVault with IntegenX, Inc. in January of 2011. He also served as an entrepreneur in residence (EIR) at Domain Associates, LLC, a leading dedicated life science venture-capital firm. Prior to these roles, Erik was chief commercial officer at Exiqon A/S, where he was responsible for global sales, marketing, and clinical affairs for two businesses: Oncology Services in a CLIA lab and Consumables Business in Life Sciences Research. In 2001 Mr. Holmlin led the formation of GeneOhm Sciences, Inc., for which, over a span of 5 years, he was director of chemistry, senior technology director, vice president of technology and business development, and vice president of marketing. At GeneOhm, he also led or participated in securing three rounds of venture financing and in the acquisition of Infectio Diagnostics, Inc., and orchestrated GeneOhm's acquisition in 2006 by Becton Dickinson. As an executive at BD, he then served as vice president of marketing and development, responsible for multiple product launches and managing more than 80 employees in three sites and two countries.
William R. LaRue has more than 25 years of experience in corporate leadership and growth strategies. As senior vice president and chief financial officer at Cadence Pharmaceuticals, Mr. LaRue oversaw the raising of more than $350 million in equity and debt and led the company through its initial public offering (IPO) in 2006 and acquisition by Mallinckrodt plc in 2014 for $1.4 billion. Mr. LaRue also served on the board of directors at Cadence, and he is currently on the board of directors of TRACON Pharmaceuticals, Inc., focused on targeted therapies for cancer and macular degeneration, and Neurelis, Inc., a private early-stage company developing product candidates for epilepsy and additional central nervous system disorders. Mr. LaRue also served as senior vice president and chief financial officer for CancerVax Corporation and was vice president and treasurer of Safeskin Corporation as well as a key member of Safeskin’s negotiating team for its acquisition by Kimberly-Clark Corporation.